Literature DB >> 8514277

Expression of tumour necrosis factor-alpha in cryptogenic fibrosing alveolitis.

J R Nash1, P J McLaughlin, D Butcher, B Corrin.   

Abstract

We have studied 15 cases of cryptogenic fibrosing alveolitis stained with a monoclonal antibody reactive with human tumour necrosis factor-alpha (TNF alpha), a cytokine that has been implicated in inflammation and fibrosis. Seven were examples of lone cryptogenic fibrosing alveolitis and eight were examples of cryptogenic fibrosing alveolitis in patients with systemic sclerosis. There was widespread staining of epithelial cells, particularly hyperplastic type II pneumocytes. Macrophages stained only weakly. In a control group of 10 patients dying of unrelated conditions, staining for TNF alpha was weak and, in the alveolar epithelium, was confined to a very occasional type II pneumocyte. The strong expression of TNF alpha in hyperplastic type II pneumocytes suggests that TNF alpha produced during alveolar epithelial regeneration may play a part in the fibrosis seen in this disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8514277     DOI: 10.1111/j.1365-2559.1993.tb00133.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  14 in total

Review 1.  Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches.

Authors:  Moisés Selman; Victor J Thannickal; Annie Pardo; David A Zisman; Fernando J Martinez; Joseph P Lynch
Journal:  Drugs       Date:  2004       Impact factor: 9.546

2.  Discoidin domain receptor 1 contributes to the survival of lung fibroblast in idiopathic pulmonary fibrosis.

Authors:  Wataru Matsuyama; Masaki Watanabe; Yuko Shirahama; Hideo Mitsuyama; Ikkou Higashimoto; Mitsuhiro Osame; Kimiyoshi Arimura
Journal:  Am J Pathol       Date:  2006-03       Impact factor: 4.307

3.  Apoptosis is a major pathway responsible for the resolution of type II pneumocytes in acute lung injury.

Authors:  R H Bardales; S S Xie; R F Schaefer; S M Hsu
Journal:  Am J Pathol       Date:  1996-09       Impact factor: 4.307

Review 4.  Pharmacologic therapies for idiopathic pulmonary fibrosis, past and future.

Authors:  Bashar S Staitieh; Elisabetta A Renzoni; Srihari Veeraraghavan
Journal:  Ann Med       Date:  2015-01-22       Impact factor: 4.709

Review 5.  Pathogenetic mechanisms in usual interstitial pneumonia/idiopathic pulmonary fibrosis.

Authors:  Eric S White; Michael H Lazar; Victor J Thannickal
Journal:  J Pathol       Date:  2003-11       Impact factor: 7.996

6.  Alveolar epithelial cells in idiopathic pulmonary fibrosis display upregulation of TRAIL, DR4 and DR5 expression with simultaneous preferential over-expression of pro-apoptotic marker p53.

Authors:  Khondoker M Akram; Nicola J Lomas; Nicholas R Forsyth; Monica A Spiteri
Journal:  Int J Clin Exp Pathol       Date:  2014-01-15

7.  Expression of a tumor necrosis factor-alpha transgene in murine lung causes lymphocytic and fibrosing alveolitis. A mouse model of progressive pulmonary fibrosis.

Authors:  Y Miyazaki; K Araki; C Vesin; I Garcia; Y Kapanci; J A Whitsett; P F Piguet; P Vassalli
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

Review 8.  Idiopathic pulmonary fibrosis: current understanding of the pathogenesis and the status of treatment.

Authors:  Nasreen Khalil; Robert O'Connor
Journal:  CMAJ       Date:  2004-07-20       Impact factor: 8.262

9.  Cellular FLICE-like inhibitory protein deviates myofibroblast fas-induced apoptosis toward proliferation during lung fibrosis.

Authors:  Regina Golan-Gerstl; Shulamit B Wallach-Dayan; Philip Zisman; Wellington V Cardoso; Ronald H Goldstein; Raphael Breuer
Journal:  Am J Respir Cell Mol Biol       Date:  2012-05-10       Impact factor: 6.914

Review 10.  Novel therapeutic approaches for pulmonary fibrosis.

Authors:  Arnab Datta; Chris J Scotton; Rachel C Chambers
Journal:  Br J Pharmacol       Date:  2011-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.